Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry

Bekadja, Mohamed-Amine; Boumendil, Ariane; Blaise, Didier; Chevallier, Patrice; Peggs, Karl S.; Salles, Gilles; Giebel, Sebastian; Marks, Reinhard; Arcese, William; Milpied, Noël; Finel, Hervé; Gorin, Norbert Claude

doi:10.1016/j.jcyt.2020.12.016

Cited by 11 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both groups showed similar platelet engraftment in our results, while the median days of hospital stay after transplantation was lower in the fresh group, but without statistical significance. The use of fresh or cryopreserved PBSC grafts did not affect the overall survival of our multiple myeloma cohort, similar to other studies 5,14,15 …”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

Background: Autologous stem cell transplantation is the standard procedure for multiple myeloma and the grafts are usually cryopreserved. Previous studies reported advantages in the use of fresh peripheral blood stem cells (PBSC) autotransplantation compared to cryopreservation of the grafts. This study compared the transplant-related outcomes of two graft preservation methods: fresh storage (4°C/72 h) and cryopreservation (À80°C).

show abstract

Section: Discussionsupporting

confidence: 90%

“…The use of fresh or cryopreserved PBSC grafts did not affect the overall survival of our multiple myeloma cohort, similar to other studies. 5,14,15 The fresh group showed significantly less adverse events despite occurring in both groups. AE grades 4 or 5 were not reported in both groups, similar to other PBSC autotransplantation studies.…”

Section: Resultsmentioning

confidence: 90%

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After apheresis, peripheral stem cells were stored at 4 °C in a blood bank refrigerator for up to 72 h. The median time to engraftment was 12 days (range 9–22) for neutrophil and 17 days for platelets (range 10–44), resulting in the use of this technique been adequate for ASCT in MM patients; 72 h is commonly considered the time limit not to exceed in order to keep an acceptable stem cell viability. However this threshold has not been clinically validated; recent evidence showed delayed engraftment in patients with lymphoma autografted with non-cryopreserved stem cells infused up to six days after collection [ 48 ]. Further, it should be highlighted that infusion of autologous fresh stem cells needs very precise planning of patients’ hospital stay, conditioning, and reinfusion, requiring an efficient program coordination.…”

Section: Considerations With Stem Cell Mobilization and Harvestingmentioning

confidence: 99%

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

Morè

Corvatta²,

Manieri

et al. 2022

Cells

View full text Add to dashboard Cite

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfilzomib and monoclonal antibody daratumumab into each phase of treatment significantly improved the efficacy of ASCT in terms of measurable residual disease (MRD) negativity, Progression Free Survival (PFS), and Overall Survival (OS). The availability of techniques such as multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for MRD assessment allowed the design of MRD-based response-adjusted trials that will define, in particular, the role of consolidation and maintenance therapies. In this review, we will provide an overview of the most recent evidence and the future prospects of ASCT in MM patients.

show abstract

“…However, it was shown very early on that marrow could not be preserved for more than 56 h [18]. In contrast, and more recently, it was observed that peripheral blood stem cell (PBSC) collected and somewhat purified by leukapharesis (LK), can survive storage at 4°C for up to 6 days but not longer, enabling carefully planned autografts to be performed in patients receiving short pre-transplant regimens [19][20][21][22][23][24]. Stem cell cryopreservation opened the door for autologous transplantation and a decade later to cord blood storage.…”

Section: Cryopreservation Of Stem Cellsmentioning

confidence: 99%

History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia

Gorin¹

2021

CHI

Self Cite

View full text Add to dashboard Cite

This review describes the development of cryopreservation, the birth of autologous stem cell transplantation (ASCT) and its past and present use to consolidate adult patients with acute myelogenous leukemia (AML). It summarizes the first autografts in patients in relapse, the experience of autografting in complete remission (CR), using bone marrow unpurged or purged in vitro with cyclophosphamide-derivatives, and the important shift to peripheral blood stem cells. The review also discusses the results of recent studies in favor of the use of ASCT to consolidate good-and intermediate-risk patients who reach CR with no detectable minimal residual disease, and those which support the inclusion of maintenance therapy post autograft with hypomethylating agents, anti-BCL-2, and, possibly, in the future, anti AML chimeric antigen receptor-T cells. Carefully applied to well-selected patients, ASCT may regain interest, because of its simplicity, its reduced toxicity, lower non-relapse mortality and better quality of life.

show abstract

Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry

Cited by 11 publications

References 21 publications

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia

Contact Info

Product

Resources

About